

Comments and Critique

Three Dimensions

Cell and Molecular Oncology

Clinical Oncology

Epidemiology

THE *EJC* in its new format has celebrated its first anniversary. The manuscript flow has more than doubled and the feedback has been good. During the first year the editors have been able to monitor and reappraise the overall thrust of the *EJC*, to sharpen its objectives with a view to realising the original goal to provide a unique forum, the special feature of which is the blend of science and clinical and population-based medicine. To achieve this the *EJC* will in future focus on three areas: cell and molecular oncology, clinical oncology and epidemiology/cancer prevention.

With regard to **cell and molecular oncology**, we are delighted to announce a new partnership between the *EJC* and the European Association for Cancer Research (EACR) which, as described by Michael Price below, will greatly expand its membership and activities. The cell and molecular oncology section of the journal—which will be available separately to members of the EACR in 1992 (as, of course will be the *EJC* as a whole)—will be an outlet for papers and other contributions from EACR members, as well as from other scientists. The emphasis placed by the *EJC* on prompt reviewing and short publication time will be maintained. Werner Franke will continue to supervise the science aspects from the *EJC* editorial office in Heidelberg with input from EACR and the scientific members of the editorial board. The *EJC* will be particularly

pleased to receive basic science papers which have immediate or longer term clinical implications.

To re-emphasise the *EJC*'s commitment to **clinical oncology**, from issue 10 there will be a new regular feature, "**case presentations from oncology centres**", in which the investigation and management of a particular clinical problem will be placed in the context of biology, changing concepts and obstacles to progress.

Through the clinical oncology editorial offices—medical oncology (Matti Aapro, Geneva), radiation oncology (Emmanuel van der Schueren, Leuven) and surgical oncology (Umberto Veronesi, Milan)—the *EJC* will continue to ensure rapid publication of high quality clinical research papers extending from clinical biology and phase 1–3 studies to applied research on psychosocial issues and health services.

During the past year, the *EJC* has been applauded for publishing high quality papers in cancer epidemiology, many of which have been stimulated by Peter Boyle from the epidemiology editorial office in Lyon. **Cancer epidemiology and prevention** will continue to receive a high priority and form the third main thrust of the journal.

Michael Peckham
Editor in Chief
European Journal of Cancer

EJC and EACR

THE EUROPEAN ASSOCIATION for Cancer Research (EACR) very much welcomes the opportunity to revitalise its affiliation with the *European Journal of Cancer* with the creation of the new section on cell and molecular oncology. *EJC* has been our official journal for over a decade. During this period, the scope of EACR activities has widened to include major biennial meetings, a forthcoming joint meeting with the American Association for Cancer Research, sponsored workshops on specialised topics and two flourishing fellowship programmes. The EACR membership has increased from a few hundred to the present number, which is approaching 1500, and with the recent election of scientists from the USSR to the membership, the authentic European character of the EACR is at last being realised.

In line with this growth and development in the EACR, it is projected that Cell and Molecular Oncology will become a focus of excellence for basic research relating to cancer. By placing

Cell and Molecular Oncology alongside sections concerned with the clinical sciences, fundamental research findings may also be assessed in the context of the cancer problem as a whole. The wide distribution of the journal, both within Europe and beyond, will ensure that research findings receive appropriate attention among the community of cancer researchers. Members of the EACR are encouraged to support this initiative by the submission of high quality manuscripts and short publication times. The association has excellent representation in the various editorial and advisory boards, and there is a genuine enthusiasm to build upon past successes of the journal to provide all cancer scientists with both an outlet for their important research communications and a major stimulus for future scientific investigation in cancer.

Michael R. Price
European Association for Cancer Research